- This event has passed.
Genostics Circulating Tumour Cells (CTCs) Seminar
December 1, 2014 @ 6:00 pm - 9:00 pm
CTC Seminar: Monitoring the effectiveness of cancer treatment is a joint-seminar with Dr. Katherina Pachmann and Dr. Fluhrer
Practitioners are invited to join practitioners at the Genostics CTC Seminar designed to bring you the latest information on how to monitor the effectiveness of cancer treatment, presented by world-renowned CTC scientist Prof. Katherina Pachmann
Circulating Tumour Cells (CTCs) are the metastasising population of cancer cells. CTCs are now well established as independent prognostic indicators of metastatic disease. CTC enumeration and analysis represents a ‘fluid-biopsy,’ with results now firmly associated with clinical outcome. Practitioners and Oncologists who are interested or are already benefiting from using CTC-tests will be in attendance.
Prof. Katherina Pachmann is a world-renowned expert in Circulating Tumour Cell science – both in research and in translational medicine. She has worked internationally in academically and scientifically acclaimed cell research centers. She will be presenting new research at COSA and the World Cancer Congress in November in Melbourne, as well as presenting seminars to practitioners in locations around Australia and New Zealand.
Dr. Joachim Fluhrer has recently been acknowledged internationally for Excellence in Integrative Medicine, and will be touring alongside Prof. Pachmann. Dr. Fluhrer brings his clinical and medical expertise to the discussion table, and is passionate about facilitating the best in evidence-based medical research for use in the clinical setting.
This seminar will be a unique opportunity to meet CTC expert scientist Prof. Pachmann and discuss clinical cases you might have with her and Dr. Fluhrer together. The seminar will include updates on the latest in CTC-technology and how it is revolutionising cancer monitoring, and will be a great chance to meet and discuss personalised cancer treatment with colleagues.
“CTC Characterisation is expected to contribute to guiding specific targeted therapies to a defined population of cancer patients within a certain therapeutic window – which is the hallmark of personalized medicine”
— Alix-Panabieres & Pantel, Clinical Chemistry 2014, 59(1): 110-8